Pulmatrix, Inc.（简称Pulmatrix）与Eos Senolytix近日宣布签署合并协议，双方将整合资源加速开发创新线粒体靶向疗法。此次合作旨在通过突破性技术手段干预细胞衰老机制，为延长人类健康寿命提供全新治疗路径。合并后的实体计划结合Pulmatrix在肺部药物递送领域的专长与Eos Senolytix在细胞衰老清除技术方面的优势，共同推进针对年龄相关疾病的下一代治疗方案。
Pulmatrix, Inc.（简称Pulmatrix）与Eos Senolytix近日宣布签署合并协议，双方将整合资源加速开发创新线粒体靶向疗法。此次合作旨在通过突破性技术手段干预细胞衰老机制，为延长人类健康寿命提供全新治疗路径。合并后的实体计划结合Pulmatrix在肺部药物递送领域的专长与Eos Senolytix在细胞衰老清除技术方面的优势，共同推进针对年龄相关疾病的下一代治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.